Direct-to-Consumer Advertising for Prescription Drugs in Canada: Beyond Good or Evil
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Canadians have always had a hard time reconciling health and mercantilism. The publicly-funded system is, in part, responsible for nourishing this collective position, as Canadians rarely have to pay physicians and hospitals directly for the health care and services they receive. Direct-to-Consumer-Advertising (DTCA) is a particularly controversial issue for Canadians, as it not only involves commercial interests in health, but also allows for the appealing possibility of greater involvement for patients in decisions related to their health. (1) DTCA for prescription drugs is, in principle, forbidden in Canada. Pharmaceutical companies are limited to aiming their advertisement solely to health professionals. However, discussion surrounding the DTCA issue remains relevant, as the federal government has indicated its interest in revising the Food and Drug Act. Key changes with respect to the of health care products are being seriously considered, notably regarding the introduction of DTCA for prescription drugs. (2) Even though the legislation restricts most DTCA, the truth is that Canadians, whether they want to be or not, are aware of it. The current loopholes in Canadian legislation and policies, combined with the fact that from the United States reaches Canada via magazines, television and the Internet, make DTCA an already-existing reality for Canadians (3). Therefore, in this article I propose stepping away from the traditional binary debate about whether DTCA is good or not in order to focus on some practical issues and solutions. I will first discuss the legislation and policies surrounding DTCA in Canada. Secondly, I will underline the lack of involvement by certain key actors in the debate. Finally, I will propose some potential solutions (should DTCA be further implemented in Canada) that would notably provide for greater involvement of these actors. The Status of DTCA Under Canadian Law The responsibility for interpreting and enforcing drug-advertising regulations lies with Health Canada. It seems that Canada, through current Canadian law on the subject, has put its foot in the door with respect to DTCA, but now doesn't know if it should step in or slam the door shut again. While DTCA is allowed for non-prescription drugs, it is, in principle, restricted for prescription drugs. (4) The Canadian Food and Drugs Act mentions that, No person shall advertise any food, drug, cosmetic or device to the general public as a treatment, preventive or cure for any of the diseases, disorders or abnormal physical states [...]. (5) The Act defines advertisement as including any representation by any means whatsoever for the purpose of directly or indirectly promoting the sale or disposal of any food, drug, cosmetic or device. (6) Whereas the applicable regulation seems quite broad on the definition of advertisement, a policy statement made by Health Canada in 1996 indicated a distinction between and information dissemination. (7) This statement had the impact of allowing help-seeking advertisement, which describes the condition the drug treats, but not the name, price, or quantity. (8) As well, reminder advertisement, which provides the name, price, or quantity of the drug without stating its use, is permitted in Canada. (9) The type of advertisement that is presently not allowed in Canada is that which links both categories of information; that is, the products' names and their specific therapeutic claims. This last type is called product claim and is permitted in the United States. However, the current capacity of Health Canada to effectively restrict real advertising remains uncertain. Various actors have expressed serious doubts about the ability of Health Canada to deal with the offenders. (10) As an illustration, it took Health Canada six months to inform Wyeth-Ayerst Canada of its contravention of the Food and Drug Regulations. …
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it